Display options
Cite
Scurr MJ, Zelek WM, Lippiatt G, et al. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers. Immunology. 2021;165(2):250-259doi: 10.1111/imm.13433.
Scurr, M. J., Zelek, W. M., Lippiatt, G., Somerville, M., Burnell, S. E. A., Capitani, L., Davies, K., Lawton, H., Tozer, T., Rees, T., Roberts, K., Evans, M., Jackson, A., Young, C., Fairclough, L., Tighe, P., Wills, M., Westwell, A. D., Morgan, B. P., Gallimore, A., & Godkin, A. (2022). Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers. Immunology, 165(2), 250-259. https://doi.org/10.1111/imm.13433
Scurr, Martin J, et al. "Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers." Immunology vol. 165,2 (2022): 250-259. doi: https://doi.org/10.1111/imm.13433
Scurr MJ, Zelek WM, Lippiatt G, Somerville M, Burnell SEA, Capitani L, Davies K, Lawton H, Tozer T, Rees T, Roberts K, Evans M, Jackson A, Young C, Fairclough L, Tighe P, Wills M, Westwell AD, Morgan BP, Gallimore A, Godkin A. Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers. Immunology. 2022 Feb;165(2):250-259. doi: 10.1111/imm.13433. Epub 2021 Dec 06. PMID: 34775604; PMCID: PMC8653009.
Copy Download .nbib Format: NLM
Share it on

Immunology. 2022 Feb;165(2):250-259. doi: 10.1111/imm.13433. Epub 2021 Dec 06.

Whole blood-based measurement of SARS-CoV-2-specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid-organ cancers.

Immunology

Martin J Scurr, Wioleta M Zelek, George Lippiatt, Michelle Somerville, Stephanie E A Burnell, Lorenzo Capitani, Kate Davies, Helen Lawton, Thomas Tozer, Tara Rees, Kerry Roberts, Mererid Evans, Amanda Jackson, Charlotte Young, Lucy Fairclough, Paddy Tighe, Mark Wills, Andrew D Westwell, B Paul Morgan, Awen Gallimore, Andrew Godkin

Affiliations

  1. Division of Infection & Immunity, School of Medicine, Cardiff University, Cardiff, UK.
  2. ImmunoServ Ltd, Cardiff, UK.
  3. School of Medicine, Systems Immunity University Research Institute, Cardiff University, Cardiff, UK.
  4. UK Dementia Research Institute Cardiff, Cardiff University, Cardiff, UK.
  5. Radyr Medical Centre, Cardiff, UK.
  6. Department of Gastroenterology & Hepatology, University Hospital of Wales, Cardiff, UK.
  7. Velindre Cancer Centre, Cardiff, UK.
  8. School of Life Sciences, University of Nottingham, Nottingham, UK.
  9. Department of Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
  10. School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK.

PMID: 34775604 PMCID: PMC8653009 DOI: 10.1111/imm.13433

Abstract

Accurate assessment of SARS-CoV-2 immunity is critical in evaluating vaccine efficacy and devising public health policies. Whilst the exact nature of effective immunity remains incompletely defined, SARS-CoV-2-specific T-cell responses are a critical feature that will likely form a key correlate of protection against COVID-19. Here, we developed and optimized a high-throughput whole blood-based assay to determine the T-cell response associated with prior SARS-CoV-2 infection and/or vaccination amongst 231 healthy donors and 68 cancer patients. Following overnight in vitro stimulation with SARS-CoV-2-specific peptides, blood plasma samples were analysed for T

© 2021 The Authors. Immunology published by John Wiley & Sons Ltd.

Keywords: COVID-19; SARS-CoV-2; T cells; antibodies; vaccine

References

  1. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489-501.e15. - PubMed
  2. Sette A, Crotty S. Pre-existing immunity to SARS-CoV-2: the knowns and unknowns. Nat Rev Immunol. 2020;20:457-8. - PubMed
  3. Riou C, Schäfer G, du Bruyn E, Goliath RT, Stek C, Mou H, et al. Rapid, simplified whole blood-based multiparameter assay to quantify and phenotype SARS-CoV-2 specific T cells. medRxiv. 2020. doi:10.1101/2020.10.30.20223099 - PubMed
  4. Le Bert N, Tan AT, Kunasegaran K, Tham CYL, Hafezi M, Chia A, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;584:457-62. - PubMed
  5. Zuo J, Dowell AC, Pearce H, Verma K, Long HM, Begum J, et al. Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. Nat Immunol. 2021;22:620-6. - PubMed
  6. Wyllie D, Mulchandani R, Jones HE, Taylor-Phillips S, Brooks T, Charlett A, et al. SARS-CoV-2 responsive T cell numbers are associated with protection from COVID-19: a prospective cohort study in keyworkers. medRxiv. 2020. doi:10.1101/2020.11.02.20222778 - PubMed
  7. Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, Kampmann B, et al. Interferon-γ release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J. 2011;37:88-99. - PubMed
  8. Murugesan K, Jagannathan P, Pham TD, Pandey S, Bonilla HF, Jacobson K, et al. Interferon-gamma release assay for accurate detection of SARS-CoV-2 T cell response. Clin Infect Dis. 2020; 73(9): e3130-e3132. doi:10.1093/cid/ciaa1537 - PubMed
  9. Petrone L, Petruccioli E, Vanini V, Cuzzi G, Najafi Fard S, Alonzi T, et al. A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clin Microbiol Infect. 2020;22(2):P286.e7-286.e13. - PubMed
  10. Le Bert N, Clapham HE, Tan AT, Chia WN, Tham CYL, Lim JM, et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. J Exp Med. 2021;218:e20202617. - PubMed
  11. Trecarichi EM, Mazzitelli M, Serapide F, Pelle MC, Tassone B, Arrighi E, et al. Clinical characteristics and predictors of mortality associated with COVID-19 in elderly patients from a long-term care facility. Sci Rep. 2020;10:20834. - PubMed
  12. Akbar AN, Gilroy DW. Aging immunity may exacerbate COVID-19. Science. 2020;369:256-7. - PubMed
  13. Sobolev O, Binda E, O'Farrell S, Lorenc A, Pradines J, Huang Y, et al. Adjuvanted influenza-H1N1 vaccination reveals lymphoid signatures of age-dependent early responses and of clinical adverse events. Nat Immunol. 2016;17:204-13. - PubMed
  14. Shehata MA, Karim NA. Influenza vaccination in cancer patients undergoing systemic therapy. Clin Med Insights Oncol. 2014;8:57-64. - PubMed
  15. Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, del Molino del Barrio I, Alaguthurai T, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;S1470-2045:00213-8. - PubMed
  16. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26:1033-6. - PubMed
  17. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al. SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Curr Protoc Microbiol. 2020;57:e100. - PubMed
  18. Moat SJ, Zelek WM, Carne E, Ponsford MJ, Bramhall K, Jones S, et al. Development of a high-throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens. Ann Clin Biochem. 2020;58(2):123-31. - PubMed
  19. Murrell I, Forde D, Zelek W, Tyson L, Chichester L, Palmer N, et al. Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: an observational cohort study. PLoS One. 2021;16:e0245382. - PubMed
  20. Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who's who of T-cell differentiation: human memory T-cell subsets. Eur J Immunol. 2013;43:2797-809. - PubMed
  21. Gallais F, Velay A, Nazon C, Wendling M-J, Partisani M, Sibilia J, et al. Intrafamilial exposure to SARS-CoV-2 associated with cellular immune response without seroconversion, France. Emerg Infect Dis. 2021;27(1):113-21. - PubMed
  22. Ward H, Cooke G, Atchison C, Whitaker M, Elliott J, Moshe M, et al. Declining prevalence of antibody positivity to SARS-CoV-2: a community study of 365,000 adults. medRxiv. 2020. doi:10.1101/2020.10.26.20219725 - PubMed
  23. Mulchandani R, Jones HE, Taylor-Phillips S, Shute J, Perry K, Jamarani S, et al. Accuracy of UK Rapid Test Consortium (UK-RTC) "AbC-19 Rapid Test" for detection of previous SARS-CoV-2 infection in key workers: test accuracy study. BMJ. 2020;371:m4262. - PubMed
  24. Bilich T, Nelde A, Heitmann JS, Maringer Y, Roerden M, Bauer J, et al. T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. Sci Transl Med. 2021;13:eabf7517. - PubMed
  25. Dalai SC, Dines JN, Snyder TM, Gittelman RM, Eerkes T, Vaney P, et al. Clinical Validation of a Novel T-cell Receptor Sequencing Assay for Identification of Recent or Prior SARS-CoV-2 Infection. medRxiv. 2021. doi:10.1101/2021.01.06.21249345 - PubMed
  26. Weiskopf D, Schmitz KS, Raadsen MP, Grifoni A, Okba NMA, Endeman H, et al. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome. Sci Immunol. 2020;5:eabd2071. - PubMed
  27. Tarke A, Sidney J, Kidd CK, Dan JM, Ramirez SI, Yu ED, et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep Med. 2021;2(2):100204. - PubMed
  28. Peng Y, Mentzer AJ, Liu G, Yao X, Yin Z, Dong D, et al. Broad and strong memory CD4. Nat Immunol. 2020;21:1336-45. - PubMed
  29. Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest. 2020;130:5235-44. - PubMed

Publication Types

Grant support